Quality of life in parkinson's disease patients following adjunctive tolcapone therapy: Results of an open-label, multicenter, community-based trial

Kapil Dev Sethi, Stewart Factor, Ray Watts

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: To examine changes in quality of life (QOL) and global clinical status after 30 days of adjunctive treatment with tolcapone, a reversible inhibitor of catechol-O-methyltransferase, in patients with fluctuating Parkinson's disease. Methods: This 30-day, multicenter, open-label, community-based study enrolled fluctuating Parkinson's disease patients to receive tolcapone 100 mg TID as an adjunct to levodopa/carbidopa. The primary end point was QOL change assessed using the Parkinson's Disease Questionnaire (PDQ)-8. Clinical change was assessed using the investigator-rated Clinical Global Impression of Improvement Scale (CGI-I). Results: Fifty-six physicians enrolled 202 patients; 138 (68%) were ≥65 years of age and 116 (57%) had Parkinson's disease for ≥5 years. The mean PDQ-8 total score improved from 42.1 to 34.8 after 30 days of tolcapone (P<.0001). Sixty-nine percent of patients improved on the CGI-I. Physicians planned to continue tolcapone beyond the 30 days in 72%, most commonly because of positive changes in motor function and overall general improvement. No patient discontinued because of liver adverse events. Conclusions: Adjunctive tolcapone treatment was associated with statistically significant improvement in QOL in fluctuating Parkinson's disease patients. A majority of patients experienced clinical benefits and continued treatment beyond the end of this study. No liver-related adverse events were reported.

Original languageEnglish (US)
Pages (from-to)27-32
Number of pages6
JournalCNS spectrums
Volume15
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Parkinson Disease
Quality of Life
Therapeutics
Physicians
Liver
tolcapone
Research Personnel

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Quality of life in parkinson's disease patients following adjunctive tolcapone therapy : Results of an open-label, multicenter, community-based trial. / Sethi, Kapil Dev; Factor, Stewart; Watts, Ray.

In: CNS spectrums, Vol. 15, No. 1, 01.01.2010, p. 27-32.

Research output: Contribution to journalArticle

@article{896ce2f4544f48dcb2a1c8437015370e,
title = "Quality of life in parkinson's disease patients following adjunctive tolcapone therapy: Results of an open-label, multicenter, community-based trial",
abstract = "Objective: To examine changes in quality of life (QOL) and global clinical status after 30 days of adjunctive treatment with tolcapone, a reversible inhibitor of catechol-O-methyltransferase, in patients with fluctuating Parkinson's disease. Methods: This 30-day, multicenter, open-label, community-based study enrolled fluctuating Parkinson's disease patients to receive tolcapone 100 mg TID as an adjunct to levodopa/carbidopa. The primary end point was QOL change assessed using the Parkinson's Disease Questionnaire (PDQ)-8. Clinical change was assessed using the investigator-rated Clinical Global Impression of Improvement Scale (CGI-I). Results: Fifty-six physicians enrolled 202 patients; 138 (68{\%}) were ≥65 years of age and 116 (57{\%}) had Parkinson's disease for ≥5 years. The mean PDQ-8 total score improved from 42.1 to 34.8 after 30 days of tolcapone (P<.0001). Sixty-nine percent of patients improved on the CGI-I. Physicians planned to continue tolcapone beyond the 30 days in 72{\%}, most commonly because of positive changes in motor function and overall general improvement. No patient discontinued because of liver adverse events. Conclusions: Adjunctive tolcapone treatment was associated with statistically significant improvement in QOL in fluctuating Parkinson's disease patients. A majority of patients experienced clinical benefits and continued treatment beyond the end of this study. No liver-related adverse events were reported.",
author = "Sethi, {Kapil Dev} and Stewart Factor and Ray Watts",
year = "2010",
month = "1",
day = "1",
doi = "10.1017/S1092852900000274",
language = "English (US)",
volume = "15",
pages = "27--32",
journal = "CNS Spectrums",
issn = "1092-8529",
publisher = "MBL Communications",
number = "1",

}

TY - JOUR

T1 - Quality of life in parkinson's disease patients following adjunctive tolcapone therapy

T2 - Results of an open-label, multicenter, community-based trial

AU - Sethi, Kapil Dev

AU - Factor, Stewart

AU - Watts, Ray

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Objective: To examine changes in quality of life (QOL) and global clinical status after 30 days of adjunctive treatment with tolcapone, a reversible inhibitor of catechol-O-methyltransferase, in patients with fluctuating Parkinson's disease. Methods: This 30-day, multicenter, open-label, community-based study enrolled fluctuating Parkinson's disease patients to receive tolcapone 100 mg TID as an adjunct to levodopa/carbidopa. The primary end point was QOL change assessed using the Parkinson's Disease Questionnaire (PDQ)-8. Clinical change was assessed using the investigator-rated Clinical Global Impression of Improvement Scale (CGI-I). Results: Fifty-six physicians enrolled 202 patients; 138 (68%) were ≥65 years of age and 116 (57%) had Parkinson's disease for ≥5 years. The mean PDQ-8 total score improved from 42.1 to 34.8 after 30 days of tolcapone (P<.0001). Sixty-nine percent of patients improved on the CGI-I. Physicians planned to continue tolcapone beyond the 30 days in 72%, most commonly because of positive changes in motor function and overall general improvement. No patient discontinued because of liver adverse events. Conclusions: Adjunctive tolcapone treatment was associated with statistically significant improvement in QOL in fluctuating Parkinson's disease patients. A majority of patients experienced clinical benefits and continued treatment beyond the end of this study. No liver-related adverse events were reported.

AB - Objective: To examine changes in quality of life (QOL) and global clinical status after 30 days of adjunctive treatment with tolcapone, a reversible inhibitor of catechol-O-methyltransferase, in patients with fluctuating Parkinson's disease. Methods: This 30-day, multicenter, open-label, community-based study enrolled fluctuating Parkinson's disease patients to receive tolcapone 100 mg TID as an adjunct to levodopa/carbidopa. The primary end point was QOL change assessed using the Parkinson's Disease Questionnaire (PDQ)-8. Clinical change was assessed using the investigator-rated Clinical Global Impression of Improvement Scale (CGI-I). Results: Fifty-six physicians enrolled 202 patients; 138 (68%) were ≥65 years of age and 116 (57%) had Parkinson's disease for ≥5 years. The mean PDQ-8 total score improved from 42.1 to 34.8 after 30 days of tolcapone (P<.0001). Sixty-nine percent of patients improved on the CGI-I. Physicians planned to continue tolcapone beyond the 30 days in 72%, most commonly because of positive changes in motor function and overall general improvement. No patient discontinued because of liver adverse events. Conclusions: Adjunctive tolcapone treatment was associated with statistically significant improvement in QOL in fluctuating Parkinson's disease patients. A majority of patients experienced clinical benefits and continued treatment beyond the end of this study. No liver-related adverse events were reported.

UR - http://www.scopus.com/inward/record.url?scp=77951928281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951928281&partnerID=8YFLogxK

U2 - 10.1017/S1092852900000274

DO - 10.1017/S1092852900000274

M3 - Article

C2 - 20394182

AN - SCOPUS:77951928281

VL - 15

SP - 27

EP - 32

JO - CNS Spectrums

JF - CNS Spectrums

SN - 1092-8529

IS - 1

ER -